Global Recombinant Human Follicle-stimulating Hormone Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Delivery：Within 72h| Full Report Selling Price |
|---|
2800.00 USD |
4200.00 USD |
5600.00 USD |
| Buy NowContact Us |
| Competitor Data Selling Price |
|---|
900.00 USD |
1350.00 USD |
1800.00 USD |
| Buy NowContact Us |
Market Overview
According to DIResearch＇s in-depth investigation and research, the global Recombinant Human Follicle-stimulating Hormone market size will reach 1,340.75 Million USD in 2025 and is projected to reach 2,010.67 Million USD by 2032, with a CAGR of 5.96% (2025-2032). Notably, the China Recombinant Human Follicle-stimulating Hormone market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Recombinant human follicle-stimulating hormone (r-hFSH) is a laboratory-engineered version of the naturally occurring hormone FSH, produced using recombinant DNA technology in cell cultures. It plays a key role in regulating reproductive processes by stimulating the growth and maturation of ovarian follicles in women and supporting sperm production in men. Clinically, r-hFSH is widely used in fertility treatments, such as controlled ovarian stimulation during in vitro fertilization (IVF), offering consistent purity and potency compared to urine-derived FSH. Its precise dosing and high biological activity make it a cornerstone in modern assisted reproductive therapies.
The major global suppliers of Recombinant Human Follicle-stimulating Hormone include Merck, Ferring, Livzon, Gedeon Richter, GenSci, Teva, ChangChun High & New Technology, ABL, Scripps Laboratories, Alphamab Oncology, Hunan Jingfeng Pharmaceutical, Qilu Pharmaceutical, Beijing SL Pharmaceutical, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Recombinant Human Follicle-stimulating Hormone. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Recombinant Human Follicle-stimulating Hormone market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Recombinant Human Follicle-stimulating Hormone market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Recombinant Human Follicle-stimulating Hormone industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Recombinant Human Follicle-stimulating Hormone Include:
Merck
Ferring
Livzon
Gedeon Richter
GenSci
Teva
ChangChun High & New Technology
ABL
Scripps Laboratories
Alphamab Oncology
Hunan Jingfeng Pharmaceutical
Qilu Pharmaceutical
Beijing SL Pharmaceutical
Recombinant Human Follicle-stimulating Hormone Product Segment Include:
75IU
150IU
Others
Recombinant Human Follicle-stimulating Hormone Product Application Include:
Infertility Treatment
Assisted Reproductive Technology
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Recombinant Human Follicle-stimulating Hormone Industry PESTEL Analysis
Chapter 3: Global Recombinant Human Follicle-stimulating Hormone Industry Porter's Five Forces Analysis
Chapter 4: Global Recombinant Human Follicle-stimulating Hormone Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Recombinant Human Follicle-stimulating Hormone Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Recombinant Human Follicle-stimulating Hormone Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Recombinant Human Follicle-stimulating Hormone Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Global Recombinant Human Follicle-stimulating Hormone Revenue and Market Share by Player
| Revenue (US$ Million) | 2020 | 2021 | 2022 | 2023 | 2024 |
| Merck | XX | XX | XX | XX | XX |
| Ferring | XX | XX | XX | XX | XX |
| Livzon | XX | XX | XX | XX | XX |
| Gedeon Richter | XX | XX | XX | XX | XX |
| GenSci | XX | XX | XX | XX | XX |
| Teva | XX | XX | XX | XX | XX |
| ChangChun High & New Technology | XX | XX | XX | XX | XX |
| ABL | XX | XX | XX | XX | XX |
| Scripps Laboratories | XX | XX | XX | XX | XX |
| Alphamab Oncology | XX | XX | XX | XX | XX |
| Hunan Jingfeng Pharmaceutical | XX | XX | XX | XX | XX |
| Qilu Pharmaceutical | XX | XX | XX | XX | XX |
| Beijing SL Pharmaceutical | XX | XX | XX | XX | XX |
| Other Companies | XX | XX | XX | XX | XX |
| Total | XX | XX | XX | XX | XX |
Related Report
Global Dydrogesterone Drug Competitive Landscape Professional Research Report 2025
Global Dydrogesterone Drug Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Global Olanzapine Competitive Landscape Professional Research Report 2025
Global Olanzapine Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Global Oligonucleotide Pool Library Competitive Landscape Professional Research Report 2025
Global Oligonucleotide Pool Library Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Global Oligonucleotide Therapeutics Competitive Landscape Professional Research Report 2025
Global Oligonucleotide Therapeutics Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Order Process
Contact
1. Fill in your contact information, and the company will quickly match the specialist to get in touch with you
2. You can also directly call our customer service hotline or add customer service WeChat
Samples
1. One on one business specialist will send the complete version of the sample
2. If you need to customize the report, professional analysts will be arranged to communicate with you one-on-one and provide you with customized samples
Payment
1. Both parties sign a report purchase contract
2. Support Paypal, Visa, UnionPay and MasterCard Payment
Delivery
1. PDF report (sent online 2-3 working days after payment)
2. WORD version report (sent online 2-3 working days after payment)
3. Paper version report (sent via EMS or DHL within 3-5 working days after payment)
After-Sales
Within six months of purchasing the report, if you have any questions about the details of our report, you can contact the report analyst at any time. The analyst will continue to follow up and solve your problem until you are satisfied
